Last reviewed · How we verify
NCT05176379
Endothelial Derived Hyperpolarization Factor and Regulation of Cerebral and Muscle Blood Flow
Phase 4 trial testing Fluconazole 150 mg in Healthy in 30 participants. Currently enrolling.
1 December 2024
Quick facts
| Lead sponsor | University of Oklahoma |
|---|---|
| Phase | Phase 4 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | single |
| Primary purpose | basic science |
| Enrollment | 30 |
| Start date | 19 February 2022 |
| Primary completion | 1 December 2024 |
| Estimated completion | 1 May 2025 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Fluconazole 150 mg — full drug profile →
Conditions studied
- Healthy — all drugs for Healthy →
Sponsor
University of Oklahoma
Who can join
Adults 18 to 30, any sex, with Healthy. Healthy volunteers can join.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Near-Infrared Spectroscopy
Time frame: up to 4 hours
Concentrations of Oxygen, deoxy, and Total Hemoglobin (micro molar) -
Transcranial Doppler Ultrasound
Time frame: up to 4 hours
middle cerebral artery blood velocity
Sponsor's own description
Most cardiometabolic diseases are characterized by increased muscle sympathetic nerve activity (MSNA) during rest and exercise which contributes to poor health outcomes. In healthy humans during muscle contraction, there is a blunting of skeletal muscle vascular responsiveness to increases in MSNA. However, the exact mechanisms involved are unknown although, best evidence suggests that the mechanism is endothelium derived, but nitric oxide (NO) and prostaglandin (PG) independent. Endothelium-derived hyperpolarizing factor (EDHF) is a NO and PG independent vasodilator in both cerebral and skeletal muscle circulations, however, it is unknown if EDHF contributes to vascular responsiveness during elevated MSNA. The application of lower body negative pressure (LBNP) is a safe and non-invasive manipulation that can be used to increase MSNA causing vasoconstriction in humans. Therefore, the purpose of this experiment is to determine if acute inhibition of EDHF alters central and peripheral vascular responses to LBNP at rest and during dynamic exercise. Thereby, providing evidence by which EDHF contributes to vascular control in healthy humans and identify it's potential as a therapeutic target for cardiometabolic diseases that are characterized by elevated MSNA
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
The effects of CYP450 inhibition on cerebrovascular control during rest and mild hypovolemia: An exploratory study in young, healthy adults.
Matney JE, Buelow AA, Mixon C, Skillett SM, et al · · 2025 · cited 1× · PMID 41420405 · DOI 10.14814/phy2.70712
Verify or expand the search:
- PubMed search for NCT05176379
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Fluconazole 150 mg
Trials testing the same drug.
- NCT07396857 — The Role of EDHFs on Blood Pressure Following a Bout of Prolonged Sitting · NA · recruiting
- NCT07342153 — Comparing the Efficacy of Oral Fluconazole Versus Oral Itraconazole in Treating Resistant Tinea Corporis · Phase 4 · recruiting
- NCT04930107 — Vulvovaginal Candidiasis in Canadian Females · EARLY_PHASE1 · active not recruiting
- NCT04734405 — A Phase IIb/III Study of Prof-001 for the Treatment of Patients With Recurrent Vulvovaginal Candidiasis (RVVC) · Phase 2, PHASE3 · unknown
Other recruiting trials for Healthy
Currently open trials in the same condition.
- NCT06707207 — Predicting Future Errors During Skill Performance · recruiting
- NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
- NCT07499414 — The Effects of the Bile Acid Supplement, 7-keto Lithocholic Acid, on Human Gut Microbiota and Risk Factors for Disease. · NA · recruiting
- NCT07496697 — Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects · NA · recruiting
- NCT06431932 — Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity · Phase 1, PHASE2 · recruiting
Other University of Oklahoma trials
Trials by the same sponsor.
- NCT07219706 — Dietary Fiber and Time Restricted Eating · NA · recruiting
- NCT07494773 — Topical Methylene Blue-Photodynamic Therapy (MB-PDT) for Burn Wound Infection · Phase 1, PHASE2 · not yet recruiting
- NCT07014605 — Smoking Cessation Program for Lao People With HIV · NA · not yet recruiting
- NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
- NCT07491653 — Fiber mHealth Intervention for Prediabetes · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05176379 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Oklahoma
- Last refreshed: 19 July 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05176379.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing